{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:08:13Z","timestamp":1740179293005,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The Utrecht Symptom Diary (USD) is a validated Dutch patient-reported outcome measurement (PROM) tool - based on the Edmonton Symptom Assessment System - to assess and monitor symptoms in cancer patients. The USD contains 11 items concerning frequently occurring symptoms in cancer patients (pain, sleeping problems, dry mouth, dysphagia, lack of appetite, abnormal stool, nausea, shortness of breath, fatigue, anxiety and depressed mood) and an item on overall well-being. For the outpatient USD 11 items concerning frequently occurring signs and symptoms in patients receiving chemotherapy and\/or targeted therapy were added to the USD: taste alteration, oral pain, weight loss, diarrhoea, hair changes, skin problems, nail problems, eye problems, tingling, concentration problems and problems with sexuality. This current study aimed to evaluate the 11 added items on this treatment specific outpatient USD in cancer patients receiving intravenous chemotherapy and\/or targeted therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Observational longitudinal retrospective cohort study including all adult outpatients with cancer receiving intravenous chemotherapy and\/or targeted therapy in an academic hospital in the Netherlands who completed at least one outpatient USD as part of routine care (2012\u20132021). Relevance, comprehensiveness as well as criterion and construct validity were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>1733 patients who completed\u2009\u2265\u20091 outpatient USD during intravenous chemotherapy and\/or targeted therapy were included for analysis. Relevance as well as comprehensiveness of the items on the outpatient USD in this patient population was shown. Criterion validation was demonstrated for all added items of the outpatient USD \u2013 except for the item on oral pain. An additional analysis showed that mouth problems were detected with both outpatient USD items oral pain and dry mouth. Construct validity was demonstrated for the items hair changes and skin and nail problems. Construct validity on eye problems was not tested due to the low number of paired outpatient USDs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The treatment specific outpatient USD is a validated PROM in outpatients with cancer receiving intravenous chemotherapy and\/or targeted therapy. Considering its validity in this broad group of patients, we think the treatment-specific outpatient USD is widely applicable. In addition to providing tailored supportive symptom care, the USD-data can be used to increase knowledge about symptom burden in daily practice in this population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00794-w","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T12:03:40Z","timestamp":1729253020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation of 11 added items of the outpatient version of the Utrecht Symptom Diary in patients receiving chemotherapy or targeted therapy"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4205-6611","authenticated-orcid":false,"given":"Josephine J.","family":"Koldenhof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernice O.","family":"Akpobome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Zweers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stance","family":"Klaasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia C. C. M.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petronella O.","family":"Witteveen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karijn P. M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"de Graeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederieke H.","family":"van der Baan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"794_CR1","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00520-012-1688-0","volume":"21","author":"CM Reilly","year":"2013","unstructured":"Reilly CM, Bruner DW, Mitchell SA et al (2013) A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer 21:1525\u20131550. https:\/\/doi.org\/10.1007\/s00520-012-1688-0","journal-title":"Support Care Cancer"},{"key":"794_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V (2018) Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 19:31\u201339. https:\/\/doi.org\/10.1007\/s40257-018-0384-3","journal-title":"Am J Clin Dermatol"},{"key":"794_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.14694\/edbk_175418","volume":"37","author":"K Mooney","year":"2017","unstructured":"Mooney K, Berry DL, Whisenant M, Sjoberg D (2017) Improving Cancer Care through the patient experience: how to use patient-reported outcomes in clinical practice. Am Soc Clin Oncol Educ Book 37:695\u2013704. https:\/\/doi.org\/10.14694\/edbk_175418","journal-title":"Am Soc Clin Oncol Educational Book"},{"key":"794_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.14694\/edbook_am.2014.34.161","volume":"34","author":"E Basch","year":"2014","unstructured":"Basch E (2014) The rationale for collecting patient-reported symptoms during routine chemotherapy. Am Soc Clin Oncol Educ Book 34:161\u2013165. https:\/\/doi.org\/10.14694\/edbook_am.2014.34.161","journal-title":"Oncol Educational Book"},{"key":"794_CR5","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1007\/s00520-018-4234-x","volume":"26","author":"G Kotronoulas","year":"2018","unstructured":"Kotronoulas G, Papadopoulou C, Simpson MF et al (2018) Using patient-reported outcome measures to deliver enhanced supportive care to people with lung cancer: feasibility and acceptability of a nurse-led consultation model. Support Care Cancer 26:3729\u20133737. https:\/\/doi.org\/10.1007\/s00520-018-4234-x","journal-title":"Support Care Cancer"},{"key":"794_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/082585979100700202","volume":"7","author":"E Bruera","year":"1991","unstructured":"Bruera E, Kuehn N, Miller MJ et al (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6\u20139","journal-title":"J Palliat Care"},{"key":"794_CR7","doi-asserted-by":"publisher","unstructured":"Hui D, Bruera E (2016) The Edmonton Symptom Assessment System 25 years later: past, present and future developments. https:\/\/doi.org\/10.1016\/j.jpainsymman.2016.10.370. J Pain Symptom Manage","DOI":"10.1016\/j.jpainsymman.2016.10.370"},{"key":"794_CR8","unstructured":"Boddaert M, Douma J, Dijxhoorn F, Bijkerk M (2017) Netherlands quality framework palliative care. In: Utrecht, 2017"},{"key":"794_CR9","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.1002\/cam4.3253","volume":"9","author":"FH van der Baan","year":"2020","unstructured":"van der Baan FH, Koldenhof JJ, de Nijs EJ et al (2020) Validation of the Dutch version of the Edmonton Symptom Assessment System. Cancer Med 9:6111\u20136121. https:\/\/doi.org\/10.1002\/cam4.3253","journal-title":"Cancer Med"},{"key":"794_CR10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/cncr.29104","volume":"121","author":"LI Wagner","year":"2015","unstructured":"Wagner LI, Schink J, Bass M et al (2015) Bringing PROMIS to practice: brief and precise symptom screening in ambulatory cancer care. Cancer 121:927\u2013934. https:\/\/doi.org\/10.1002\/cncr.29104","journal-title":"Cancer"},{"key":"794_CR11","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1097\/NCC.0000000000000792","volume":"44","author":"M IJzerman-Korevaar","year":"2021","unstructured":"IJzerman-Korevaar M, de Graeff A, Heijckmann S et al (2021) Use of a symptom diary on oncology wards. Cancer Nurs 44:E209\u2013E220. https:\/\/doi.org\/10.1097\/NCC.0000000000000792","journal-title":"Cancer Nurs"},{"key":"794_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/JNN.0000000000000400","volume":"50","author":"M IJzerman-Korevaar","year":"2018","unstructured":"IJzerman-Korevaar M, Snijders TJ, Teunissen SCCM et al (2018) Symptom monitoring in glioma patients: development of the Edmonton Symptom Assessment System glioma module. J Neurosci Nurs 50:381\u2013387. https:\/\/doi.org\/10.1097\/JNN.0000000000000400","journal-title":"J Neurosci Nurs"},{"key":"794_CR13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jpainsymman.2022.02.013","volume":"63","author":"JJ Koldenhof","year":"2022","unstructured":"Koldenhof JJ, van der Baan FH, Verberne EG et al (2022) Patient-reported outcomes during checkpoint inhibition: insight into symptom burden in daily clinical practice. J Pain Symptom Manage 63:997\u20131005. https:\/\/doi.org\/10.1016\/j.jpainsymman.2022.02.013","journal-title":"J Pain Symptom Manage"},{"key":"794_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1634\/theoncologist.2010-0298","volume":"16","author":"C Pinto","year":"2011","unstructured":"Pinto C, Barone CA, Girolomoni G et al (2011) Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 16:228\u2013238. https:\/\/doi.org\/10.1634\/theoncologist.2010-0298","journal-title":"Oncologist"},{"key":"794_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40265-021-01507-z","volume":"81","author":"BH Fortes","year":"2021","unstructured":"Fortes BH, Tailor PD, Dalvin LA (2021) Ocular toxicity of targeted anticancer agents. Drugs 81:771\u2013823","journal-title":"Drugs"},{"key":"794_CR16","unstructured":"NVPO (2017) Detecteren behoefte psychosociale zorg. https:\/\/richtlijnendatabase.nl\/richtlijn\/detecteren_behoefte_psychosociale_zorg\/meest_geschikte_instrument\/welke_instrumenten_zijn_er.html. Accessed 12 Oct 2022"},{"key":"794_CR17","unstructured":"van Trigt I, Boddaert M (2018) Meetinstrumenten in De Palliatieve Zorg"},{"key":"794_CR18","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/cncr.23622","volume":"113","author":"MA Tuinman","year":"2008","unstructured":"Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JE (2008) Screening and referral for psychosocial distress in oncologic practice: use of the distress thermometer. Cancer 113:870\u2013878. https:\/\/doi.org\/10.1002\/cncr.23622","journal-title":"Cancer"},{"key":"794_CR19","doi-asserted-by":"publisher","unstructured":"Ownby K, PhD RN, AOCN ACHPN, ANP-BC K (2019) Use of the distress thermometer in clinical practice. J Adv Pract Oncol 10. https:\/\/doi.org\/10.6004\/jadpro.2019.10.2.7","DOI":"10.6004\/jadpro.2019.10.2.7"},{"key":"794_CR20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s11136-018-1829-0","volume":"27","author":"CB Terwee","year":"2018","unstructured":"Terwee CB, Prinsen CAC, Chiarotto A et al (2018) COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual Life Res 27:1159\u20131170. https:\/\/doi.org\/10.1007\/s11136-018-1829-0","journal-title":"Qual Life Res"},{"key":"794_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jclinepi.2010.02.006","volume":"63","author":"T Mokkink","year":"2010","unstructured":"Mokkink T, Patrick, et al (2010) The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported. J Clin Epidemiol 63:737\u2013745. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.02.006","journal-title":"J Clin Epidemiol"},{"key":"794_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jpainsymman.2006.10.015","volume":"34","author":"SCCM Teunissen","year":"2007","unstructured":"Teunissen SCCM, Wesker W, Kruitwagen C et al (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 34:94\u2013104. https:\/\/doi.org\/10.1016\/j.jpainsymman.2006.10.015","journal-title":"J Pain Symptom Manage"},{"issue":"11","key":"794_CR23","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1177\/1049909118775660","volume":"35","author":"JKMKYMTMY Kako","year":"2018","unstructured":"Kako J, Kobayashi M, Kanno Y, Ogawa A, Miura T, Matsumoto Y (2018) The optimal cutoff point for expressing revised Edmonton Symptom Assessment System scores as binary data indicating the presence or absence of symptoms. Am J Hospice Palliat Med 35(11):1390\u20131393. https:\/\/doi.org\/10.1177\/1049909118775660","journal-title":"Am J Hospice Palliat Med"},{"key":"794_CR24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jpainsymman.2012.06.007","volume":"45","author":"WH Oldenmenger","year":"2013","unstructured":"Oldenmenger WH, De Raaf PJ, De Klerk C, Van Der Rijt CCD (2013) Cut points on 0\u201310 numeric rating scales for symptoms included in the Edmonton symptom assessment scale in cancer patients: a systematic review. J Pain Symptom Manage 45:1083\u20131093. https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.06.007","journal-title":"J Pain Symptom Manage"},{"key":"794_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jpainsymman.2015.09.011","volume":"51","author":"T Yamaguchi","year":"2016","unstructured":"Yamaguchi T, Morita T, Nitto A et al (2016) Establishing cutoff points for defining symptom severity using the Edmonton Symptom Assessment System-revised Japanese version. J Pain Symptom Manage 51:292\u2013297. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.09.011","journal-title":"J Pain Symptom Manage"},{"key":"794_CR26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","volume":"27","author":"CAC Prinsen","year":"2018","unstructured":"Prinsen CAC, Mokkink LB, Bouter LM et al (2018) COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res 27:1147\u20131157. https:\/\/doi.org\/10.1007\/s11136-018-1798-3","journal-title":"Qual Life Res"},{"key":"794_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A et al (2011) pROC: an open-source package for R and S\u2009+\u2009to analyze and compare ROC curves. BMC Bioinformatics 12:77. https:\/\/doi.org\/10.1186\/1471-2105-12-77","journal-title":"BMC Bioinformatics"},{"key":"794_CR28","unstructured":"Mokkink LB, Prinsen CAC, Patrick DL et al (2019) COSMIN study design checklist for patient-reported outcome measurement instruments"},{"key":"794_CR29","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055.CME","volume":"80","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Shapiro J, Goldfarb S et al (2019) CME Part 1: hair disorders in cancer patients. J Am Acad Dermatol 80:1179\u20131196. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.055.CME","journal-title":"J Am Acad Dermatol"},{"key":"794_CR30","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40257-018-0378-1","volume":"19","author":"P Suchonwanit","year":"2018","unstructured":"Suchonwanit P, McMichael AJ (2018) Alopecia in Association with Malignancy: a review. Am J Clin Dermatol 19:853\u2013865","journal-title":"Am J Clin Dermatol"},{"key":"794_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-9966-31-50","volume":"31","author":"G Fabbrocini","year":"2012","unstructured":"Fabbrocini G, Cameli N, Romano MC et al (2012) Chemotherapy and skin reactions. J Exp Clin Cancer Res 31:1. https:\/\/doi.org\/10.1186\/1756-9966-31-50","journal-title":"J Experimental Clin Cancer Res"},{"key":"794_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000486338","volume":"94","author":"F Petrelli","year":"2018","unstructured":"Petrelli F, Ardito R, Ghidini A et al (2018) Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and meta-analysis. Oncol (Switzerland) 94:191\u2013199. https:\/\/doi.org\/10.1159\/000486338","journal-title":"Oncol (Switzerland)"},{"key":"794_CR33","doi-asserted-by":"publisher","first-page":"e1886","DOI":"10.1634\/theoncologist.2020-0698","volume":"25","author":"V Ostwal","year":"2020","unstructured":"Ostwal V, Kapoor A, Mandavkar S et al (2020) Effect of a structured teaching module including intensive prophylactic measures on reducing the incidence of capecitabine-induced hand-foot syndrome: results of a prospective randomized Phase III Study. Oncologist 25:e1886\u2013e1892. https:\/\/doi.org\/10.1634\/theoncologist.2020-0698","journal-title":"Oncologist"},{"key":"794_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4081\/oncol.2020.442","volume":"14","author":"JJM Kwakman","year":"2020","unstructured":"Kwakman JJM, Elshot YS, Punt CJA, Koopman M (2020) Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev 14:57\u201363","journal-title":"Oncol Rev"},{"key":"794_CR35","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00520-012-1645-y","volume":"21","author":"DS Borkar","year":"2013","unstructured":"Borkar DS, Lacouture ME, Basti S (2013) Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer 21:1167\u20131174. https:\/\/doi.org\/10.1007\/s00520-012-1645-y","journal-title":"Support Care Cancer"},{"key":"794_CR36","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1001\/jamaoncol.2017.1269","volume":"3","author":"YS Yap","year":"2017","unstructured":"Yap YS, Kwok LL, Syn N et al (2017) Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine\u2013induced hand-foot syndrome a randomized clinical trial. JAMA Oncol 3:1538\u20131545. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1269","journal-title":"JAMA Oncol"},{"key":"794_CR37","doi-asserted-by":"publisher","first-page":"102376","DOI":"10.1016\/j.ctrv.2022.102376","volume":"105","author":"A Ali","year":"2022","unstructured":"Ali A, Shah AA, Jeang LJ et al (2022) Emergence of ocular toxicities associated with novel anticancer therapeutics: what the oncologist needs to know. Cancer Treat Rev Apr 105:102376. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102376","journal-title":"Cancer Treat Rev Apr"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00794-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T12:06:52Z","timestamp":1729253212000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00794-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00794-w","relation":{},"ISSN":["2509-8020"],"issn-type":[{"type":"electronic","value":"2509-8020"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was not considered subject to the Medical Research Involving Human Subjects Act by the institutional review board of the UMC Utrecht (METC number 15\/087).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JK, BA, DZ, AG, SK, PW, FB: no conflicts of interests. ST: Chair Dutch Palliative Care Association, secondary job 0.5 fte. KS: received consulting fees from Abbvie, Pierre Fabre, Sairopa; Research funding: TigaTx, Bristol Myers Squibb, Philips, Genmab. All paid to institution.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}